Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox

Lucy Deng; Laura K Lopez; Catherine Glover; Patrick Cashman; Renee Reynolds; Kristine Macartney; Nicholas Wood

doi:10.1001/jama.2023.7683

Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox

JAMA. 2023 Jun 20;329(23):2091-2094. doi: 10.1001/jama.2023.7683.

Authors

Lucy Deng¹, Laura K Lopez¹, Catherine Glover¹, Patrick Cashman², Renee Reynolds², Kristine Macartney¹, Nicholas Wood¹

Affiliations

¹ National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
² School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia.

No abstract available

Plain language summary

This study uses data collected by Australia’s vaccine safety surveillance system to examine the adverse event profile of the modified vaccinia Ankara–Bavarian Nordic vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
Humans
Immunization / adverse effects
Monkeypox virus
Mpox (monkeypox)* / prevention & control
Smallpox Vaccine* / adverse effects
Smallpox Vaccine* / therapeutic use
Vaccinia virus
Vaccinia* / etiology
Vaccinia* / prevention & control

Substances

Antibodies, Viral
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
Smallpox Vaccine